ArticleAntonie van Leeuwenhoek2026
Probiotic novel strain Lactobacillus reuteri MRD01 alleviates dextran sulfate sodium-induced colitis in male mice by promoting intestinal barrier integrity.
Article in Antonie van Leeuwenhoek, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Intestinal barrier dysfunction contributes to the progression of inflammatory bowel disease (IBD), yet current therapies provide limited symptom relief, are associated with substantial long-term adverse effects, and exhibit high recurrence rates. Lactobacillus reuteri (L. reuteri), a probiotic with strong colonisation capacity in the gastrointestinal tract, produces metabolites that regulate intestinal microecology. This study explored the therapeutic efficacy and underlying mechanisms of a newly isolated strain, L. reuteri MRD01, in a dextran sodium sulfate (DSS)-induced colitis model. Our results showed that L. reuteri MRD01 effectively mitigated DSS-induced colitis in mice. Administration of MRD01 alleviated body weight loss and partially recovered body weight, attenuated colon shortening, and significantly reduced the disease activity index (DAI), spleen index, and histopathological damage scores. The strain increased MUC2 expression and goblet cell numbers, possibly enhancing mucin secretion and reinforcing the intestinal mucosal barrier. Additionally, MRD01 improved epithelial integrity by upregulating zonula occludens-1 (ZO-1) and occludin expression, and reducing the leakage of fluorescein isothiocyanate-dextran (FITC-dextran; FD4). The strain modulated the inflammatory response by downregulating interleukin (IL)-1β, IL-6, and tumour necrosis factor-α (TNF-α), whereas enhancing IL-10 expression. This cytokine modulation rebalanced macrophage polarisation and inhibited the Toll-like receptor 4 (TLR4)-nuclear factor-κB (NF-κB)-NLR family pyrin domain containing 3 (NLRP3) inflammasome pathway, thereby attenuating systemic inflammation. Mechanistically, L. reuteri MRD01 altered the gut microbial composition, contributing to the restoration of intestinal homeostasis. These results substantially revealed that L. reuteri MRD01 alleviated colitis by synergistically enhancing mucosal protection, epithelial integrity, immune homeostasis, and microbial balance. These findings support its therapeutic potential as a probiotic-based strategy for IBD management.
Indexed as
Identifiers
41931124What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.